US20020019369A1 - Injectable drug delivery systems with cyclodextrin-polymer based hydrogels - Google Patents

Injectable drug delivery systems with cyclodextrin-polymer based hydrogels Download PDF

Info

Publication number
US20020019369A1
US20020019369A1 US09/861,182 US86118201A US2002019369A1 US 20020019369 A1 US20020019369 A1 US 20020019369A1 US 86118201 A US86118201 A US 86118201A US 2002019369 A1 US2002019369 A1 US 2002019369A1
Authority
US
United States
Prior art keywords
polymer
poly
cyclodextrin
composition
ethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/861,182
Other versions
US8003125B2 (en
Inventor
Jun Li
Hanry Yu
Kam Leong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to INSTITUTE OF MATERIALS RESEARCH & ENGINEERING reassignment INSTITUTE OF MATERIALS RESEARCH & ENGINEERING ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YU, HANRY, LEONG, KAM, LI, JUN
Publication of US20020019369A1 publication Critical patent/US20020019369A1/en
Priority to PCT/IB2002/001687 priority Critical patent/WO2002094324A1/en
Assigned to AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH reassignment AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INSTITUTE OF MATERIALS RESEARCH AND ENGINEERING
Application granted granted Critical
Publication of US8003125B2 publication Critical patent/US8003125B2/en
Assigned to CRG SERVICING LLC, AS ADMINISTRATIVE AGENT reassignment CRG SERVICING LLC, AS ADMINISTRATIVE AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OMEROS CORPORATION
Assigned to OMEROS CORPORATION reassignment OMEROS CORPORATION RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CRG SERVICING LLC
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the invention is directed to injectable drug delivery systems with cyclodextrin poly(ethylene glycol) polymer based hydrogels.
  • thermosensitive block copolymers have also been proposed as sustained release matrix for drugs. They have the advantage that there is no chemical reaction involved in the gel formation. These copolymer hydrogels are usually designed for macromolecular drugs such as protein and hormone drugs. The disadvantage of such temperature sensitive hydrogels is the practicality of using such a gel in injection.
  • the article describes poly(ethylene glycol)s (PEG) of high molecular weight which was found to form complexes with alpha-cyclodextrin (alpha-CD) in aqueous solutions to give gels in a wide range of concentration.
  • PEG poly(ethylene glycol)s
  • alpha-CD alpha-cyclodextrin
  • the time of gelation decreased with increase in alpha-CD and PEG concentration, indicating that the gal formed during complex formation between alpha-CD chains.
  • the time of gelation increases in the molecular weight of PEG, indicating that the PEG chains penetrate alpha CD cavities from the ends of PEG and are included in alpha CDS.
  • X-Ray powder diffraction studies showed that the gel consists of both complexed alpha-CD and uncomplexed alpha CD, indicating partial inclusion of PEG chains by alpha-CD.
  • a further article explores polymers as potential drug delivery systems that display a physicochemical response to stimuli.
  • Stimuli studied to date include chemical substances and changes in temperature, pH, and electric field.
  • Homopolymer or copolymers of N-isopropylacrylamide and poly(ethylene oxide)poly(propylene oxide)-poly(ethylene oxide) are typical examples of thermosensitive polymers, but their use in drug delivery is problematic because they are toxic and nonbiodegradable.
  • Biodegradable polymers used for drug delivery to date have mostly been in the form of injectable microspheres or implant systems, which require complicated fabrication processes using organic solvents. Such systems have the disadvantage that the use of organic solvents can cause denaturation when protein drugs are to be encapsulated. Furthermore, the solid form requires surgical insertion, which often results in tissue irritation and damage, Thermosensitive, biodegradable hydrogels may be synthesized using blocks of poly(ethylene oxide) and poly(L-lactic acid). Aqueous solutions of these copolymers form a sol around 45° C. In this form, the polymer is injectable. On subsequent rapid cooling to body temperature, the loaded copolymer forms a gel that act as a sustained release matrix for drugs. (Jeong B, Bae Y H, Lee D S, Kim S W Biodegradable Block Copolymers as Drug Delivery Systems Nature 388:(6645) 860-862 Aug. 28, 1997.)
  • Another article (Kwon I C, Bac Y H, Kim S W, Electrically Erodible Polymer Gel for Controlled Release of Drugs Nature 354:(6351) 291-293 Nov. 28, 1991) is directed to new controlled drug-delivery systems being explored to overcome the disadvantages of conventional dosage forms.
  • stimulated drug delivery has been used to overcome the tolerance problems that occur with a constant delivery rate, to mimic the physiological pattern of hormonal concentration, and to supply drugs on demand.
  • Stimuli sensitive polymers which are potentially useful for pulsed drug delivery, experience changes in either their structure or their chemical properties in response to change in environmental conditions.
  • Environmental stimuli include temperature, pH, light (ultraviolet or visible), electric field or certain chemicals.
  • volume changes of stimuli sensitive gel networks are particularly responsive to external stimuli, but swelling is slow to occur. Such systems also provide insight into intermolecular interactions.
  • the polymeric system rapidly changes from a solid state to solution in response to small electric currents, by disintegration of the solid polymer complex into water-soluble polymers. The modulated release of insulin, and by extension other macromolecules, can be achieved with this polymeric system.
  • hydrogel system for the delivery and controlled release of drugs into the body. It is desired that the process of forming the hydrogel be simple and easy. It is also desired that the properties of the hydrogels be tunable with different copolymers thus allowing delivery and controlled release of a variety of drugs, including protein drugs, and vaccines.
  • the invention is directed to a cyclodextrin polymer-based injectable composition
  • a cyclodextrin polymer-based injectable composition comprising cyclodextrin, a polymer which is capable of forming a hydrogel with the cyclodextrin, and a pharmacologically effective amount of at least one drug; wherein the polymer is selected from poly(ethylene glycol), derivatives thereof, or a copolymer with a poly(ethylene glycol) segment
  • the copolymer with a poly(ethylene glycol) segment may include a polymer selected from the group consisting of polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acid)s, polypeptides, and proteins.
  • the cyclodextrin may be naturally synthesized by microorganisms or artificially synthesized.
  • the drug is preferably in a pharmaceutically acceptable injectable aqueous fluid.
  • the invention is further directed to the cyclodextrin polymer-based injectable composition described above and further containing a secondary polymer which complexes with the drug, conjugates the drug, or both.
  • the secondary polymer may be a polymer selected from the group consisting of polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acid)s, polypeptides, and proteins.
  • the secondary polymer may be a di- or mono-functional polymer or polyionic polymer with poly(ethylene glycol) segments.
  • the invention is further directed to a method of treating a condition requiring pharmacological treatment which comprises injecting into the body a cyclodextrin polymer-based injectable composition comprising cyclodextrin a polymer which is capable of forming a hydrogel with the cyclodextrin, and a pharmacologically effective amount of at least one drug; wherein the polymer is selected from poly(ethylene glycol), derivatives thereof, or a copolymer with a poly(ethylene glycol) segment.
  • the injection may be subcutaneous or intramuscular.
  • FIG. 1 depicts the release of dextrin-FITC from a hydrogel formed from alphacyclodextrin and linear poly(ethylene glycol) with different molecular weights.
  • FIG. 2 depicts the release of dextrin-FITC from hydrogels formed from alphacyclodextrin and Pluronic polymer poly(ethylene glycol)-poly(propylene glycol)poly(ethylene glycol) with different molecular weights and different ratios between poly(ethylene glycol) and poly(propylene glycol) segments.
  • the invention is based on the discovery that gel formation during supramolecular self-assembly between the components forms an injectable hydrogel.
  • Supramolecular self-assembly concerns the spontaneous association of multiple molecular components into a specific phase having well-defined microscopic organization and macroscopic characteristics.
  • drugs can be delivered in a sustained manner from an in vivo matrix or carrier formed from a cyclodextrin polymer-based injectable hydrogel.
  • the injectable composition is a physically cross-linked hydrogel that carries a drug to be released.
  • the hydrogel is bioabsorbable, thermosensitive, and thixotropic, and and undergoes reversion between gel and sol under certain conditions.
  • Bioabsorbable means the polymer can disappear from its initial application site in the body with or without degradation of the dispersed polymer molecules.
  • the gel-sol transition temperature is generally above room temperature, which depends on the composition of the gel, as well as on the chemical structure and molecular weight of PEG or PEG copolymers.
  • the formation of the hydrogel is generally very simple and easy.
  • the properties of the hydrogels are tunable with different copolymers thus allowing delivery of a variety of drugs, including protein drugs, and vaccines, and also allows for the sustained, controlled release of the drugs, genes, vaccines, and the like.
  • the hydrogel gel may be adjusted to be a more flexible hydrogel or a more rigid hydrogen.
  • the hydrogel structure can be tailored to have variable viscosity and drug release rates. Structures with positive charge or with higher hydrophobicity could be used to yield a more sustained release.
  • the invention is directed to a cyclodextrin polymer-based injectable hydrogel prepared from a cyclodextrin, a polymer capable of forming hydrogel with the cyclodextrin, and at least one drug.
  • the hydrogel provides a sustained, controlled release matrix for the drug.
  • the drug is in a pharmaceutically acceptable injectable aqueous fluid and may be any drug suitable for injection.
  • Suitable drugs include, but are not limited to, analgesics, anesthetics, antiarthritics, antiasthmas, anticoagulants, anticonvulsants, antidepressants, antidiabetics, antineplastics, antipsychotics, antihypertensives, antibiotics, antihistamines, decongestants, anti-inflammatories, muscle relaxants, peptide drugs, anti-parasitic drugs, antiviral drugs, genes, and vaccines.
  • the drug is in a macromolecular form or in a low molecular weight form.
  • Low molecular weight drugs may be conjugated to, for example, poly(ethylene glycol) to form a macromolecule.
  • the drug used herein is defined to encompass not only compounds or species which are inherently pharmaceutically or biological active but also material which include one or more of these active compounds or species.
  • the hydrogel may also carry DNA nanospheres for sustained, controlled release of the DNA nanospheres.
  • DNA nanospheres are nanoparticles synthesized by salt-induced complex coacervation of DNA and polycations such as gelatin and chitosan as gene delivery vehicles (Leong, K W, et al., DNA-polycation nanospheres as non-vial gene delivery vehicles, Journal of Controlled Release 53: 183-193, 1998).
  • PEG copolymers with DNA condensing or binding segments may form hydrogels with cyclodextrin, while the polymers condense or bind DNA and form DNA nanospheres in the hydrogels.
  • the pharmaceutically acceptable injectable aqueous fluid may be, but is not limited to, injectable saline.
  • the aqueous fluid may also contain buffering agents and/or preservatives.
  • buffering agents include, but are not limited to, alkali or alkali earth carbonates, phosphates, bicarbonates, citrates, borates, acetates, and succinates.
  • Suitable preservatives include, but are not limited to, sodium bisulfite, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimersol, phenylmercuric borate, parabens, benzyl alcohol and phenylethanol.
  • Cyclodextrins are a series of natural cyclic oligosaccharides composed of six, seven, eight, or more D (+) glycopyranose units linked by alpha 1, 4 linkages. Cyclodextrins are biodegradable and biocompatible and may be naturally or artificially synthesized Cyclodextrin may be synthesized naturally by microorganisms, for example. Artificially modified cyclodextrins allow manipulation of its properties to improve their solubility, complex-forming capability, and specificity, and other properties. Cyclodextrin used herein refers to all forms of the natural and artificially modified forms.
  • Suitable cyclodextrins include ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ cyclodextrin and derivatives thereof, including hydrophobic derivatives, hydrophilic derivatives, charged cyclodextrins, and the like.
  • the polymer is bioabsorbable/biodegradable, biocompatible, and is capable of forming hydrogel with cyclodextrin.
  • Bioabsorbable means the polymer can disappear from its initial application site in the body with or without degradation of the dispersed polymer molecules.
  • Biodegradable means that the polymer can break down or degrade within the body to nontoxic components by hydrolysis or enzymatic degradation.
  • Biocompatible means that all of the components are nontoxic in the body.
  • the polymer is a poly(ethylene glycol), a derivative thereof, or a copolymer that reacts with the poly(ethylene glycol) segment.
  • the polymer can also be poly(propylene glycol) or other poly(alkylene glycols). Higher molecular weight poly(ethylene glycol) is also called poly(ethylene oxide).
  • Preferably the polymer is poly(ethylene glycol).
  • the copolymer may be any one of a variety of biodegradable and biocompatible copolymers that contain ethylene glycol units which can form hydrogels with cyclodextrins such as polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acids), polypeptides, or a proteins.
  • the poly(ethylene glycol) may have different forms and different end groups.
  • the poly(ethylene glycol) derivatives may have different structures, e.g. star-shaped poly(ethylene glycol), comb-like poly(ethylene glycol), etc.
  • the poly(ethylene glycol) may be modified molecules, e.g. pegylated polysaccharides, pegylated poly(amino acid)s, pegylated proteins, etc.
  • the poly(ethylene glycol) derivatives or copolymers may have poly(ethylene glyol) or polypropylene oxide) segment(s) at the end(s), in which the middle segment carries positive charge.
  • polyamine derivatized poly(ethylene glycol), e.g. pegylated poly(ethylene imine), pegylated polylysine may be used.
  • Poly(ethylene glycol) block copolymers with poly(propylene oxide), including an pluronic polymers (Poloxamers) may also be used.
  • Different molecular weight of each segments, and weight ratio of the blocks, and different sequences may be used such as PEO-PPO-PEO (Pluronic), PPO-PEO-PPO (Pluronic-R), PEO-PPO, etc.
  • the molecular weight of the polymer is preferably between 1,000 and 50,000, more preferably between 5,000 and 35,000.
  • the polymer is in an aqueous solution.
  • typical aqueous solutions contain about 1% to about 80% polymer, preferably about 10% to about 40%.
  • a non-limiting example commercially available is 28% poly(ethylene glycol).
  • the cyclodextrin and polymer are combined in sufficient amounts and ratios to provide an injectable hydrogel.
  • the hydrogel can be made to pass through needles up to 27 G.
  • the amount of cyclodextrin to polymer is, but not limited to, 0.275 in weight.
  • Suitable polymers useful in the invention include PLURONIC (BASF Corp.) surfactant which is a group of poly(ethylene oxide)-polypropylene oxide)poly(ethylene oxide) triblock copolymers also known as poloxamers.
  • PLURONIC BASF Corp.
  • the PEG block at both ends is able to complex with ⁇ -cyclodextrin, just like the PEG molecules.
  • PLURONIC polymers have unique surfactant abilities and extremely low toxicity and immunogenic responses. These products have low acute oral and dermal toxicity and low potential for causing irritation or sensitization, and the general chronic and subchronic toxicity is low.
  • PLURONIC polymers are among a small number of surfactants that have been approved by the FDA for direct use in medical applications and as food additives (BASF (1990) Pluronic & Tetronic Surfactants, BASF Co., Mount Olive, N.J.). Recently, several PLURONIC polymers have been found to enhance the therapeutic effect of drugs, and the gene transfer efficiency mediated by adenovirus. (March K L, Madison J E, Trapnell B C. (1995) “Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implication for cardiovascular gene therapy.” Hum Gene Therapy 6(1): 41-53, 1995).
  • hydrogels Two functional domains are essential: a poly(ethylene glycol), derivative or copolymer thereof, and a cyclodextrin moiety threaded onto the polymer.
  • a bulky blocking group may be conjugated to the end of polymer chain via a biodegradable linkage, e.g. L-phenylalanine, L-tryptophan, nicotinyl groups, etc..
  • a biodegradable linkage is required for the end group conjugation.
  • the composition may also contain a secondary polymer which may complex with the drug, conjugate the drug, or both.
  • the secondary polymer may be a polyester, polyurethane, polyamide, polyether, polysaccharide, poly(amino acid), polypeptide, or a protein.
  • the secondary polymer is a di- or mono-functional polymer or polyionic polymer with polyethylene glycol) segments.
  • the hydrogel formulations act not only as a matrix but also a carrier of the drugs. This means that the drug is not only physically entrapped in the hydrogel but also complexed or conjugated to the molecules that form the hydrogel.
  • the secondary polymer may also be used to alter the properties, such as porosity and viscosity, of the matrix hydrogel.
  • the amount of the second polymer should be sufficient to achieve the desired result. e.g. a sufficient amount to complex with and/or conjugate the drug.
  • the injectable composition may be injected into the body of the patient in any suitable manner.
  • the hydrogen may be administered by subcutaneous, intramuscular, intradermal, and intracranial injection.
  • the hydrogel can be administrated to a confined area or tissue to achieve a higher local concentration of the drug.
  • the particular drug used in the hydrogel is the type which a patient would require for pharmacological treatment of the condition from which the patient is suffering.
  • the cyclodextrin-polymer based injectable composition may be prepared in any suitable manner. Generally, the drug in aqueous solution is combined with the cyclodextrin. The solution is mixed and then the poly(ethylene glycol) component is added. The mixture is cooled, generally to a temperature of 0° C. to 25° C., preferably to refrigeration temperatures such as 4° C. The resulting pro)duct is a white viscous hydrogel.
  • the pH of the hydrogel is generally, about 6.5 to about 7.8, which are suitable pH levels for injection into the body.
  • the pH level may be adjusted by any suitable acid or base such as hydrochloric acid or sodium hydroxide.
  • the solution was mixed with 0.15 ml of an aqueous solution of Pluronic polymer (molecular weight mom 2,900 to 35,000, PPG/PEG ration between 0 and 3.0) with a typical concentration of 0.40 g/ml.
  • Pluronic polymer molecular weight mom 2,900 to 35,000, PPG/PEG ration between 0 and 3.0
  • the mixture was placed into a 0.6-ml cuvette, and then incubated in a 40° C. water bath for one hour.
  • the cuvette was then kept in a refrigerator at 4° C. overnight, allowing the mixture to form a viscous gel.
  • the resulting gels were injectable hydrogel formulations. The gel can pass through needles wit different gauges.

Abstract

A cyclodextrin polymer-based injectable composition comprising cyclodextrin, a polymer which is capable of forming a hydrogel with the cyclodextrin, and a pharmacologically effective amount of at least one drug. The polymer is selected from poly(ethylene glycol), derivatives thereon or a copolymer with a poly(ethylene glycol) segment. The copolymer with a poly(ethylene glycol) segment may include a polymer selected from the group consisting of polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acid)s, polypeptides, and proteins. The composition may be injected subcutaneously, intramuscularly, intradermally, or intracranially.

Description

    FIELD OF THE INVENTION
  • The invention is directed to injectable drug delivery systems with cyclodextrin poly(ethylene glycol) polymer based hydrogels. [0001]
    • BACKGROUND OF THE INVENTION
  • A variety of polymers used for controlled release and deliver of drugs have been developed in the past 20 years. Most of the polymers are formed into implants or injectable microspheres. Such polymers are, and must be, biodegradable and biocompatible. [0002]
  • In order to form suitable forms of polymers, complicated fabrication processes are required which typically involve organic solvents. The use of organic solvents, however, may cause denaturation of some protein drugs and even traces of an organic solvent may be toxic. [0003]
  • Polymer hydrogels have been explored for drug delivery and controlled release. For example, chemically cross-linked polymer hydrogels have been used as implants. Some injectable drug delivery systems form chemically cross-led hydrogels in the body after injection. However, the chemical reactions occurring in The body may cause tissue irritation and damage. [0004]
  • In situ formed hydrogels from thermosensitive block copolymers have also been proposed as sustained release matrix for drugs. They have the advantage that there is no chemical reaction involved in the gel formation. These copolymer hydrogels are usually designed for macromolecular drugs such as protein and hormone drugs. The disadvantage of such temperature sensitive hydrogels is the practicality of using such a gel in injection. [0005]
  • In 1994, June Li and co-workers reported the formation of hydrogels between linear poly(ethylene glycol)s and cyclodextrin. However, since then, there has been few articles on injectable drug delivery systems. In recent years, S. W. Kim et al published a few papers on injectable drug delivery systems using thermosensitive or electrically sensitive hydrogels formed from biodegradable block copolymers. [0006]
  • The article describes poly(ethylene glycol)s (PEG) of high molecular weight which was found to form complexes with alpha-cyclodextrin (alpha-CD) in aqueous solutions to give gels in a wide range of concentration. The time of gelation decreased with increase in alpha-CD and PEG concentration, indicating that the gal formed during complex formation between alpha-CD chains. The time of gelation increases in the molecular weight of PEG, indicating that the PEG chains penetrate alpha CD cavities from the ends of PEG and are included in alpha CDS. X-Ray powder diffraction studies showed that the gel consists of both complexed alpha-CD and uncomplexed alpha CD, indicating partial inclusion of PEG chains by alpha-CD. Further, the gel-melting temperature increased with increases in PEG molecular weight and alpha-CD concentration, and decreased with increase in PEG concentrations, suggesting that gelation results from the formation of longer or shorter domains of alpha-CD-PEG inclusion complexes respectively. (Li J, Harada A Kamachi M., Sol-Gel Transition During Inclusion Complex-Formation between Alpha-Cyclodextrin and High Molecular-Weight Poly(ethylene glycol)s in Aqueous Solution. [0007] Polymer Journal 26:(9) 1019-1026 1994.
  • A further article explores polymers as potential drug delivery systems that display a physicochemical response to stimuli. Stimuli studied to date include chemical substances and changes in temperature, pH, and electric field. Homopolymer or copolymers of N-isopropylacrylamide and poly(ethylene oxide)poly(propylene oxide)-poly(ethylene oxide) are typical examples of thermosensitive polymers, but their use in drug delivery is problematic because they are toxic and nonbiodegradable. [0008]
  • Biodegradable polymers used for drug delivery to date have mostly been in the form of injectable microspheres or implant systems, which require complicated fabrication processes using organic solvents. Such systems have the disadvantage that the use of organic solvents can cause denaturation when protein drugs are to be encapsulated. Furthermore, the solid form requires surgical insertion, which often results in tissue irritation and damage, Thermosensitive, biodegradable hydrogels may be synthesized using blocks of poly(ethylene oxide) and poly(L-lactic acid). Aqueous solutions of these copolymers form a sol around 45° C. In this form, the polymer is injectable. On subsequent rapid cooling to body temperature, the loaded copolymer forms a gel that act as a sustained release matrix for drugs. (Jeong B, Bae Y H, Lee D S, Kim S W Biodegradable Block Copolymers as Drug Delivery Systems [0009] Nature 388:(6645) 860-862 Aug. 28, 1997.)
  • Another article (Kwon I C, Bac Y H, Kim S W, Electrically Erodible Polymer Gel for Controlled Release of Drugs [0010] Nature 354:(6351) 291-293 Nov. 28, 1991) is directed to new controlled drug-delivery systems being explored to overcome the disadvantages of conventional dosage forms. For example, stimulated drug delivery has been used to overcome the tolerance problems that occur with a constant delivery rate, to mimic the physiological pattern of hormonal concentration, and to supply drugs on demand. Stimuli sensitive polymers, which are potentially useful for pulsed drug delivery, experience changes in either their structure or their chemical properties in response to change in environmental conditions. Environmental stimuli include temperature, pH, light (ultraviolet or visible), electric field or certain chemicals. Volume changes of stimuli sensitive gel networks are particularly responsive to external stimuli, but swelling is slow to occur. Such systems also provide insight into intermolecular interactions. The polymeric system rapidly changes from a solid state to solution in response to small electric currents, by disintegration of the solid polymer complex into water-soluble polymers. The modulated release of insulin, and by extension other macromolecules, can be achieved with this polymeric system.
  • It is desired to have an improved hydrogel system for the delivery and controlled release of drugs into the body. It is desired that the process of forming the hydrogel be simple and easy. It is also desired that the properties of the hydrogels be tunable with different copolymers thus allowing delivery and controlled release of a variety of drugs, including protein drugs, and vaccines. [0011]
    • SUMMARY OF THE INVENTION
  • The invention is directed to a cyclodextrin polymer-based injectable composition comprising cyclodextrin, a polymer which is capable of forming a hydrogel with the cyclodextrin, and a pharmacologically effective amount of at least one drug; wherein the polymer is selected from poly(ethylene glycol), derivatives thereof, or a copolymer with a poly(ethylene glycol) segment The copolymer with a poly(ethylene glycol) segment may include a polymer selected from the group consisting of polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acid)s, polypeptides, and proteins. The cyclodextrin may be naturally synthesized by microorganisms or artificially synthesized. The drug is preferably in a pharmaceutically acceptable injectable aqueous fluid. [0012]
  • The invention is further directed to the cyclodextrin polymer-based injectable composition described above and further containing a secondary polymer which complexes with the drug, conjugates the drug, or both. The secondary polymer may be a polymer selected from the group consisting of polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acid)s, polypeptides, and proteins. The secondary polymer may be a di- or mono-functional polymer or polyionic polymer with poly(ethylene glycol) segments. [0013]
  • The invention is further directed to a method of treating a condition requiring pharmacological treatment which comprises injecting into the body a cyclodextrin polymer-based injectable composition comprising cyclodextrin a polymer which is capable of forming a hydrogel with the cyclodextrin, and a pharmacologically effective amount of at least one drug; wherein the polymer is selected from poly(ethylene glycol), derivatives thereof, or a copolymer with a poly(ethylene glycol) segment. The injection may be subcutaneous or intramuscular.[0014]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 depicts the release of dextrin-FITC from a hydrogel formed from alphacyclodextrin and linear poly(ethylene glycol) with different molecular weights. [0015]
  • FIG. 2 depicts the release of dextrin-FITC from hydrogels formed from alphacyclodextrin and Pluronic polymer poly(ethylene glycol)-poly(propylene glycol)poly(ethylene glycol) with different molecular weights and different ratios between poly(ethylene glycol) and poly(propylene glycol) segments. [0016]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The invention is based on the discovery that gel formation during supramolecular self-assembly between the components forms an injectable hydrogel. Supramolecular self-assembly concerns the spontaneous association of multiple molecular components into a specific phase having well-defined microscopic organization and macroscopic characteristics. It was discovered that drugs can be delivered in a sustained manner from an in vivo matrix or carrier formed from a cyclodextrin polymer-based injectable hydrogel. The injectable composition is a physically cross-linked hydrogel that carries a drug to be released. [0017]
  • The hydrogel is bioabsorbable, thermosensitive, and thixotropic, and and undergoes reversion between gel and sol under certain conditions. Bioabsorbable means the polymer can disappear from its initial application site in the body with or without degradation of the dispersed polymer molecules. The gel-sol transition temperature is generally above room temperature, which depends on the composition of the gel, as well as on the chemical structure and molecular weight of PEG or PEG copolymers. [0018]
  • The formation of the hydrogel is generally very simple and easy. In addition, the properties of the hydrogels are tunable with different copolymers thus allowing delivery of a variety of drugs, including protein drugs, and vaccines, and also allows for the sustained, controlled release of the drugs, genes, vaccines, and the like. For example, the hydrogel gel may be adjusted to be a more flexible hydrogel or a more rigid hydrogen. The hydrogel structure can be tailored to have variable viscosity and drug release rates. Structures with positive charge or with higher hydrophobicity could be used to yield a more sustained release. [0019]
  • The invention is directed to a cyclodextrin polymer-based injectable hydrogel prepared from a cyclodextrin, a polymer capable of forming hydrogel with the cyclodextrin, and at least one drug. The hydrogel provides a sustained, controlled release matrix for the drug. [0020]
  • The drug is in a pharmaceutically acceptable injectable aqueous fluid and may be any drug suitable for injection. Suitable drugs include, but are not limited to, analgesics, anesthetics, antiarthritics, antiasthmas, anticoagulants, anticonvulsants, antidepressants, antidiabetics, antineplastics, antipsychotics, antihypertensives, antibiotics, antihistamines, decongestants, anti-inflammatories, muscle relaxants, peptide drugs, anti-parasitic drugs, antiviral drugs, genes, and vaccines. [0021]
  • The drug is in a macromolecular form or in a low molecular weight form. Low molecular weight drugs may be conjugated to, for example, poly(ethylene glycol) to form a macromolecule. The drug used herein is defined to encompass not only compounds or species which are inherently pharmaceutically or biological active but also material which include one or more of these active compounds or species. [0022]
  • The hydrogel may also carry DNA nanospheres for sustained, controlled release of the DNA nanospheres. DNA nanospheres are nanoparticles synthesized by salt-induced complex coacervation of DNA and polycations such as gelatin and chitosan as gene delivery vehicles (Leong, K W, et al., DNA-polycation nanospheres as non-vial gene delivery vehicles, [0023] Journal of Controlled Release 53: 183-193, 1998). PEG copolymers with DNA condensing or binding segments may form hydrogels with cyclodextrin, while the polymers condense or bind DNA and form DNA nanospheres in the hydrogels.
  • The pharmaceutically acceptable injectable aqueous fluid may be, but is not limited to, injectable saline. If desired, the aqueous fluid may also contain buffering agents and/or preservatives. Suitable buffering agents include, but are not limited to, alkali or alkali earth carbonates, phosphates, bicarbonates, citrates, borates, acetates, and succinates. Suitable preservatives include, but are not limited to, sodium bisulfite, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimersol, phenylmercuric borate, parabens, benzyl alcohol and phenylethanol. [0024]
  • Cyclodextrins are a series of natural cyclic oligosaccharides composed of six, seven, eight, or more D (+) glycopyranose units linked by [0025] alpha 1, 4 linkages. Cyclodextrins are biodegradable and biocompatible and may be naturally or artificially synthesized Cyclodextrin may be synthesized naturally by microorganisms, for example. Artificially modified cyclodextrins allow manipulation of its properties to improve their solubility, complex-forming capability, and specificity, and other properties. Cyclodextrin used herein refers to all forms of the natural and artificially modified forms. Suitable cyclodextrins include α-cyclodextrin, β-cyclodextrin, γcyclodextrin and derivatives thereof, including hydrophobic derivatives, hydrophilic derivatives, charged cyclodextrins, and the like.
  • The polymer is bioabsorbable/biodegradable, biocompatible, and is capable of forming hydrogel with cyclodextrin. Bioabsorbable means the polymer can disappear from its initial application site in the body with or without degradation of the dispersed polymer molecules. Biodegradable means that the polymer can break down or degrade within the body to nontoxic components by hydrolysis or enzymatic degradation. Biocompatible means that all of the components are nontoxic in the body. [0026]
  • The polymer is a poly(ethylene glycol), a derivative thereof, or a copolymer that reacts with the poly(ethylene glycol) segment. The polymer can also be poly(propylene glycol) or other poly(alkylene glycols). Higher molecular weight poly(ethylene glycol) is also called poly(ethylene oxide). Preferably the polymer is poly(ethylene glycol). The copolymer may be any one of a variety of biodegradable and biocompatible copolymers that contain ethylene glycol units which can form hydrogels with cyclodextrins such as polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acids), polypeptides, or a proteins. [0027]
  • The poly(ethylene glycol) may have different forms and different end groups. For example, the poly(ethylene glycol) derivatives may have different structures, e.g. star-shaped poly(ethylene glycol), comb-like poly(ethylene glycol), etc. The poly(ethylene glycol) may be modified molecules, e.g. pegylated polysaccharides, pegylated poly(amino acid)s, pegylated proteins, etc. The poly(ethylene glycol) derivatives or copolymers may have poly(ethylene glyol) or polypropylene oxide) segment(s) at the end(s), in which the middle segment carries positive charge. In addition polyamine derivatized poly(ethylene glycol), e.g. pegylated poly(ethylene imine), pegylated polylysine may be used. [0028]
  • Poly(ethylene glycol) block copolymers with poly(propylene oxide), including an pluronic polymers (Poloxamers) may also be used. Different molecular weight of each segments, and weight ratio of the blocks, and different sequences may be used such as PEO-PPO-PEO (Pluronic), PPO-PEO-PPO (Pluronic-R), PEO-PPO, etc. [0029]
  • The molecular weight of the polymer is preferably between 1,000 and 50,000, more preferably between 5,000 and 35,000. Preferably the polymer is in an aqueous solution. For example, typical aqueous solutions contain about 1% to about 80% polymer, preferably about 10% to about 40%. A non-limiting example commercially available is 28% poly(ethylene glycol). [0030]
  • The cyclodextrin and polymer are combined in sufficient amounts and ratios to provide an injectable hydrogel. The hydrogel can be made to pass through needles up to 27 G. Typically, the amount of cyclodextrin to polymer is, but not limited to, 0.275 in weight. [0031]
  • Suitable polymers useful in the invention include PLURONIC (BASF Corp.) surfactant which is a group of poly(ethylene oxide)-polypropylene oxide)poly(ethylene oxide) triblock copolymers also known as poloxamers. The PEG block at both ends is able to complex with α-cyclodextrin, just like the PEG molecules. PLURONIC polymers have unique surfactant abilities and extremely low toxicity and immunogenic responses. These products have low acute oral and dermal toxicity and low potential for causing irritation or sensitization, and the general chronic and subchronic toxicity is low. In fact, PLURONIC polymers are among a small number of surfactants that have been approved by the FDA for direct use in medical applications and as food additives (BASF (1990) Pluronic & Tetronic Surfactants, BASF Co., Mount Olive, N.J.). Recently, several PLURONIC polymers have been found to enhance the therapeutic effect of drugs, and the gene transfer efficiency mediated by adenovirus. (March K L, Madison J E, Trapnell B C. (1995) “Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implication for cardiovascular gene therapy.” [0032] Hum Gene Therapy 6(1): 41-53, 1995).
  • One skilled in the art recognizes that other related hydrogels can be used. Two functional domains are essential: a poly(ethylene glycol), derivative or copolymer thereof, and a cyclodextrin moiety threaded onto the polymer. A bulky blocking group may be conjugated to the end of polymer chain via a biodegradable linkage, e.g. L-phenylalanine, L-tryptophan, nicotinyl groups, etc.. A biodegradable linkage is required for the end group conjugation. [0033]
  • The composition may also contain a secondary polymer which may complex with the drug, conjugate the drug, or both. The secondary polymer may be a polyester, polyurethane, polyamide, polyether, polysaccharide, poly(amino acid), polypeptide, or a protein. Preferably the secondary polymer is a di- or mono-functional polymer or polyionic polymer with polyethylene glycol) segments. In the case where drugs conjugate or complex to the hydrogels, then the hydrogel formulations act not only as a matrix but also a carrier of the drugs. This means that the drug is not only physically entrapped in the hydrogel but also complexed or conjugated to the molecules that form the hydrogel. The secondary polymer may also be used to alter the properties, such as porosity and viscosity, of the matrix hydrogel. The amount of the second polymer should be sufficient to achieve the desired result. e.g. a sufficient amount to complex with and/or conjugate the drug. [0034]
  • The injectable composition may be injected into the body of the patient in any suitable manner. For example, the hydrogen may be administered by subcutaneous, intramuscular, intradermal, and intracranial injection. The hydrogel can be administrated to a confined area or tissue to achieve a higher local concentration of the drug. The particular drug used in the hydrogel is the type which a patient would require for pharmacological treatment of the condition from which the patient is suffering. [0035]
  • The cyclodextrin-polymer based injectable composition may be prepared in any suitable manner. Generally, the drug in aqueous solution is combined with the cyclodextrin. The solution is mixed and then the poly(ethylene glycol) component is added. The mixture is cooled, generally to a temperature of 0° C. to 25° C., preferably to refrigeration temperatures such as 4° C. The resulting pro)duct is a white viscous hydrogel. [0036]
  • The pH of the hydrogel is generally, about 6.5 to about 7.8, which are suitable pH levels for injection into the body. The pH level may be adjusted by any suitable acid or base such as hydrochloric acid or sodium hydroxide. [0037]
  • The following examples are offered by way of illustration and are not intended to limit the invention in any manner. [0038]
    • EXAMPLES Example 1
  • Preparation of the injectable hydrogel formulation with linear poly(ethylene glycol) with different molecular weight. In a 0.30 ml of α-cyclodextrin aqueous solution (0.145 g/ml) was dissolved 3.0 mg of fluorescein isothiocyanate labeled dextran (dextran FITC, molecular weight 20,000). The solution was mixed with 0.15 ml of an aqueous solution of PEG (molecular weight from 8,000 to 100,000) with a typical concentration of 0.40 g/ml. The mixture was placed into a 0.6-ml cuvette, and then incubated in a 40° C. water bath for one hour. The cuvette was then kept in a refrigerator at 4° C. overnight, allowing the composition to form a viscous gel. The resulting gels were injectable hydrogel formulations The gel can pass through needles with different gauges. [0039]
    • Example 2
  • Release of dextran-FITC from hydrogen forming from alpha cyclodextrin and linear poly(ethylene glycol) with different molecular weights (FIG. 1). For in vitro release studies, the cuvettes with hydrogels prepared in Example 1 were placed upside down in a test tube with 12 ml of water and incubated in a 37° C. water bath. The water was changed in determined intervals of time. The fluorescence intensity was read from 200 microliters samples. Results are plotted in FIG. 1 as cumulative fluorescence released versus time. The values plotted in the figure represent the average of samples from three separate hydrogels. The release rate decreases sharply with an increase in the molecular weight of PEG up to 35,000, presumably because of the chain entanglement effect and different complex stability. The release rate is quite steady with time for gels formed with PEG 35,000 and 100,000. [0040]
    • Example 3
  • Preparation of the injectable hydrogel formulation with Puronic polymer poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) with different molecular weights and different ratio between polyethylene glycol) and poly(propylene glycol) segments. In 0.30 αl of α-cyclodextrin aqueous solution (0.145 g/ml) was dissolved 3.0 mg of fluorescein isothiocyanate labeled dextran (dextran-FITC, molecular weight 20,000). The solution was mixed with 0.15 ml of an aqueous solution of Pluronic polymer (molecular weight mom 2,900 to 35,000, PPG/PEG ration between 0 and 3.0) with a typical concentration of 0.40 g/ml. The mixture was placed into a 0.6-ml cuvette, and then incubated in a 40° C. water bath for one hour. The cuvette was then kept in a refrigerator at 4° C. overnight, allowing the mixture to form a viscous gel. The resulting gels were injectable hydrogel formulations. The gel can pass through needles wit different gauges. [0041]
    • Example 4
  • Release of dextran-FITC from hydrogels forming from alpha-cyclodextrin and Pluronic polymer poly(ethylene glycol)poly(propylene glycol)-poly(ethylene glycol) with different molecular weights and different ratios between poly(ethylene glycol) and poly(propylene glycol) segments. (FIG. 2). For in vitro release studies, the cuvettes with hydrogels prepared in Example 3 were placed upside down in a test tube with 12 ml of water and incubated in a 37° C. water bath. The water was changed in determined intervals of time. The fluorescence intensity was read from 200 microliters samples. Results are plotted in FIG. 2 as cumulative fluorescence released versus time. The values plotted in the figure represent the average of samples Tom three separate hydrogels. The result shows that more sustained release kinetics may be obtained with Pluronic polymer PFG-PPG-PEG of lower molecular weight over PEG homopolymer. The higher ratio of PPO segment provides extra intermolecular hydrophobic interaction and reduces the dissolution rate of the gel. [0042]

Claims (15)

We claim:
1. A cyclodextrin polymer-based injectable composition comprising cyclodextrin, a polymer which is capable of forming a hydrogel with the cyclodextrin, and a pharmacologically effective amount of at least one drug; wherein the polymer is selected from poly(ethylene glycol), derivatives thereof, or a copolymer with a poly(ethylene glycol) segment.
2. The composition of claim 1 wherein the drug is in a pharmaceutically acceptable injectable aqueous fluid.
3. The composition of claim 1 or claim 2 wherein the cyclodextrin is naturally synthesized by microorganisms.
4. The composition of claim 1 or claim 2 wherein the cyclodextrin is artificially synthesized.
5. The composition of any of claims 1-4 wherein the polymer capable of forming a hydrogel with cyclodextrin is a copolymer of polyethylene glycol) and a polymer selected from the group consisting of polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acid)s, polypeptides, and proteins.
6. The composition of any of claims 1-5 further comprising a secondary polymer which complexes with the drug, conjugates the drug, or both.
7. The composition of claim 6 wherein the secondary polymer is a polymer selected from the group consisting of polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acid)s, polypeptides, and proteins.
8. The composition of claim 6 wherein the secondary polymer is a di- or mono-functional polymer or polyionic polymer with poly(ethylene glycol) segments.
9. The composition of any of claims 1-8 wherein the drug is in a macromolecular form.
10. The composition of any of claims 1-9 wherein the composition is injected subcutaneously, intramuscularly, intradermally, or intracranially.
11. The composition of ay of claims 1-9 further comprising a buffering agent or a preservative.
12. A method of treating a condition requiring pharmacological treatment which comprises injecting into a body a cyclodextrin polymer-based injectable hydrogel comprising cyclodextrin, a polymer which is capable of forming a hydrogel with the cyclodextrin, and a pharmacologically effective amount of at least one drug; wherein the polymer is selected from poly(ethylene glycol), derivatives thereof, or a copolymer with a poly(ethylene glycol) segment.
13. The method of claim 12 wherein the polymer capable of forming a hydrogel with cyclodextrin is a copolymer of poly(ethylene glycol) and a polymer selected from the group consisting of polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acid)s, polypeptides, and proteins.
14. The method of claim 12 or 13 wherein the composition further comprises a secondary polymer which complexes with the drug, conjugates the drug, or both.
15. The method of any of claims 12-13 wherein the composition is injected subcutaneously, intramuscularly, intradermally, or intracranially.
US09/861,182 2000-05-19 2001-05-18 Injectable drug delivery systems with cyclodextrin-polymer based hydrogels Expired - Fee Related US8003125B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/001687 WO2002094324A1 (en) 2001-05-18 2002-05-17 Injectable drug delivery systems with cyclodextrin-polymer based hydrogels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG200002754A SG98393A1 (en) 2000-05-19 2000-05-19 Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
SG200002754-0 2000-05-19

Publications (2)

Publication Number Publication Date
US20020019369A1 true US20020019369A1 (en) 2002-02-14
US8003125B2 US8003125B2 (en) 2011-08-23

Family

ID=20430590

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/861,182 Expired - Fee Related US8003125B2 (en) 2000-05-19 2001-05-18 Injectable drug delivery systems with cyclodextrin-polymer based hydrogels

Country Status (2)

Country Link
US (1) US8003125B2 (en)
SG (1) SG98393A1 (en)

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236205A1 (en) * 2002-06-21 2003-12-25 Zhang David Y. Hybridization signal amplification method (HSAM) nanostructures for diagnostic and therapeutic uses
WO2004009664A2 (en) 2002-07-19 2004-01-29 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US20050106230A1 (en) * 2003-11-17 2005-05-19 Young Janel E. Drug-enhanced adhesion prevention
US20050283224A1 (en) * 2004-06-22 2005-12-22 Scimed Life Systems, Inc. Implantable medical devices with antimicrobial and biodegradable matrices
US20060002937A1 (en) * 2004-06-10 2006-01-05 University Of Leicester Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US20060052823A1 (en) * 2004-08-31 2006-03-09 Mirizzi Michael S Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US20060177852A1 (en) * 2001-12-12 2006-08-10 Do-Coop Technologies Ltd. Solid-fluid composition
US20060212055A1 (en) * 2005-01-25 2006-09-21 Karabey Halil I Expandable occlusive structure
US20060211643A1 (en) * 2005-02-03 2006-09-21 Agency For Science, Technology And Research Polycations capable of forming complexes with nucleic acids
US20060211599A1 (en) * 2003-10-31 2006-09-21 Wakamoto Pharmaceutical Co., Ltd. Reversibly heat-gelable aqueous composition
US20060282159A1 (en) * 2003-11-17 2006-12-14 Taheri Syde A Temporary absorbable venous occlusive stent and superficial vein treatment method
US20070009528A1 (en) * 2003-05-12 2007-01-11 Natlmmune A/S Antibodies to masp-2
US20070031420A1 (en) * 1997-04-03 2007-02-08 Jensenius Jens C MASP-2, a complement-fixing enzyme, and uses for it
WO2007077561A2 (en) * 2006-01-04 2007-07-12 Do-Coop Technologies Ltd. Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
US20070248640A1 (en) * 2006-04-20 2007-10-25 Karabey Halil I Occlusive implant and methods for hollow anatomical structure
CN100371020C (en) * 2006-01-27 2008-02-27 中山大学 In situ quick preparation method of injectable supermolecular structure water gel and its uses
US7356368B2 (en) 2004-07-21 2008-04-08 Boston Scientific Scimed, Inc. Light-activated anti-infective coatings and devices made thereof
US20090004296A1 (en) * 2006-01-04 2009-01-01 Do-Coop Technologies Ltd. Antiseptic Compositions and Methods of Using Same
US20090253613A1 (en) * 2006-01-04 2009-10-08 Do-Coop Technologies Ltd. Solid-Fluid Composition
US20100041103A1 (en) * 2007-01-04 2010-02-18 Do-Coop Technologies Ltd. Composition and method for enhancing cell growth and cell fusion
US20100074899A1 (en) * 2004-06-10 2010-03-25 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US20100086929A1 (en) * 2007-01-04 2010-04-08 Do-Coop Technologies Ltd. Detection of analytes
US20100233266A1 (en) * 2009-03-13 2010-09-16 Cleek Robert L Articles and methods of treating vascular conditions
WO2010120541A2 (en) 2009-03-31 2010-10-21 University Of Washington Compositions and methods for modulating the activity of complement regulatory proteins on target cells
FR2944700A1 (en) * 2009-04-23 2010-10-29 Centre Nat Rech Scient METHOD OF FORMING EMULSIONS BASED ON CYCLODEXTRIN POLYMERS AND LIPOPHILIC COMPOUNDS, EMULSIONS THUS OBTAINED, AND COMPOSITIONS COMPRISING SAID EMULSIONS
WO2011047346A1 (en) 2009-10-16 2011-04-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US20110274725A1 (en) * 2008-09-16 2011-11-10 Louis Breton Decomposable biocompatible hydrogels and system and method for using same
WO2011156761A1 (en) 2010-06-10 2011-12-15 University Of Washington Through Its Center For Commercialization Methods and systems for adenovirus interaction with desmoglein 2 (dsg2)
WO2012139081A2 (en) 2011-04-08 2012-10-11 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
WO2013180834A2 (en) 2012-04-06 2013-12-05 Omeros Corporation Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
WO2013192240A2 (en) 2012-06-18 2013-12-27 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
WO2014052322A1 (en) 2012-09-25 2014-04-03 University Of Washington Through Its Center For Commercialization Desmoglein 2 (dsg2) binding proteins and uses therefor
WO2014113759A1 (en) 2013-01-18 2014-07-24 University Of Washington Through Its Center For Commercialization Theragnostic particles
WO2014144542A2 (en) 2013-03-15 2014-09-18 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2013245532B2 (en) * 2009-03-13 2014-09-25 W. L. Gore & Associates, Inc. Articles and methods of treating vascular conditions
WO2015023961A1 (en) 2013-08-15 2015-02-19 International Flavors & Fragrances Inc. Polyurea or polyurethane capsules
US9011860B2 (en) 2011-05-04 2015-04-21 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
WO2015058143A1 (en) 2013-10-17 2015-04-23 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US20150306231A1 (en) * 2013-01-28 2015-10-29 Terumo Kabushiki Kaisha Stabilized protein gel preparation
CN105534878A (en) * 2015-12-07 2016-05-04 四川大学 Preparation of dual-responsive injectable supramolecular intelligent hydrogel
WO2016172699A1 (en) 2015-04-24 2016-10-27 International Flavors & Fragrances Inc. Delivery systems and methods of preparing the same
EP3101171A1 (en) 2015-06-05 2016-12-07 International Flavors & Fragrances Inc. Malodor counteracting compositions
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2017143174A1 (en) 2016-02-18 2017-08-24 International Flavors & Fragrances Inc. Polyurea capsule compositions
WO2017161364A1 (en) 2016-03-18 2017-09-21 International Flavors & Fragrances Inc. Silica microcapsules and methods of preparing same
EP3300794A2 (en) 2016-09-28 2018-04-04 International Flavors & Fragrances Inc. Microcapsule compositions containing amino silicone
EP3425036A1 (en) 2017-05-30 2019-01-09 International Flavors & Fragrances Inc. Branched polyethyleneimine microcapsules
WO2019036460A1 (en) 2017-08-15 2019-02-21 Omeros Corporation Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
US10639369B2 (en) 2016-08-01 2020-05-05 Omeros Corporation Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
WO2020131956A1 (en) 2018-12-18 2020-06-25 International Flavors & Fragrances Inc. Hydroxyethyl cellulose microcapsules
US10736960B2 (en) 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
US10870708B2 (en) 2016-03-31 2020-12-22 University Of Leicester Methods for inhibiting angiogenesis in a subject in need thereof
US11045544B2 (en) 2013-03-15 2021-06-29 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
CN115350100A (en) * 2022-07-08 2022-11-18 横琴孔雀大讲堂教育科技有限公司 Hydrogel microcapsule wrapping bioactive components, preparation method thereof and application thereof in cosmetics
EP4124383A1 (en) 2021-07-27 2023-02-01 International Flavors & Fragrances Inc. Biodegradable microcapsules
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
EP4154974A1 (en) 2021-09-23 2023-03-29 International Flavors & Fragrances Inc. Biodegradable microcapsules
EP4209265A1 (en) 2022-01-07 2023-07-12 International Flavors & Fragrances Inc. Biodegradable chitosan microcapsules
EP4209264A1 (en) 2016-09-16 2023-07-12 International Flavors & Fragrances Inc. Microcapsule compositions stabilized with viscosity control agents
EP4212239A1 (en) 2022-01-14 2023-07-19 International Flavors & Fragrances Inc. Biodegradable prepolymer microcapsules
WO2023194821A1 (en) 2022-04-03 2023-10-12 Qrons Inc. Therapeutic polypseudorotaxane hydrogels
US11807641B2 (en) 2019-12-04 2023-11-07 Omeros Corporation MASP-2 inhibitors and methods of use

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028209A1 (en) 2012-08-14 2014-02-20 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4449938A (en) * 1982-02-19 1984-05-22 Lee Pharmaceuticals, Inc. Endodontic filling and sealing composition
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5482719A (en) * 1992-10-30 1996-01-09 Guillet; James E. Drug delivery systems
US5855900A (en) * 1994-09-24 1999-01-05 Nobuhiko; Yui Supramolecular-structured biodegradable polymeric assembly for drug delivery
US6096303A (en) * 1997-07-31 2000-08-01 Medical College Of Georgia Research Institute, Inc. Method to enhance treatment of cystic tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5143724A (en) 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69311538D1 (en) 1992-03-12 1997-07-17 Alkermes Inc ACTH CONTAINED MICROBALLS WITH CONTROLLED DISCHARGE
WO1994001483A1 (en) 1992-07-02 1994-01-20 Collagen Corporation Biocompatible polymer conjugates
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
KR100297541B1 (en) 1992-12-13 2001-11-26 마티에우 디올라이티 Methods for the preparation of controlled release pharmaceutical formulations and pharmaceutical formulations prepared by the method
DE4327063A1 (en) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenone particles with modified physicochemical properties
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
AU706541B2 (en) 1995-06-09 1999-06-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
PT949905E (en) 1996-12-20 2001-12-28 Alza Corp DELAYED EFFECT INJECTABLE GEL COMPOSITION AND PROCESS FOR THEIR PREPARATION
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1999009149A1 (en) 1997-08-01 1999-02-25 Massachusetts Institute Of Technology Three-dimensional polymer matrices
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US5939453A (en) 1998-06-04 1999-08-17 Advanced Polymer Systems, Inc. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
ATE356637T1 (en) 1998-12-04 2007-04-15 California Inst Of Techn DRUGS CONTAINING SUPRAMOLECULAR COMPLEXES
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1173517A4 (en) 1999-04-26 2006-06-28 California Inst Of Techn In situ forming hydrogels

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4449938A (en) * 1982-02-19 1984-05-22 Lee Pharmaceuticals, Inc. Endodontic filling and sealing composition
US5482719A (en) * 1992-10-30 1996-01-09 Guillet; James E. Drug delivery systems
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5855900A (en) * 1994-09-24 1999-01-05 Nobuhiko; Yui Supramolecular-structured biodegradable polymeric assembly for drug delivery
US6096303A (en) * 1997-07-31 2000-08-01 Medical College Of Georgia Research Institute, Inc. Method to enhance treatment of cystic tumors

Cited By (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9441262B2 (en) 1997-04-03 2016-09-13 Helion Biotech Aps MASP-2, a complement fixing enzyme, and uses for it
US20070031420A1 (en) * 1997-04-03 2007-02-08 Jensenius Jens C MASP-2, a complement-fixing enzyme, and uses for it
US8551790B2 (en) 1997-04-03 2013-10-08 Helion Biotech Aps MASP 2, a complement-fixing enzyme, and uses for it
US20060210552A1 (en) * 1998-10-20 2006-09-21 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US20090081305A1 (en) * 2001-12-12 2009-03-26 Do-Coop Technologies Ltd. Compositions and Methods for Enhancing In-Vivo Uptake of Pharmaceutical Agents
US20100267007A1 (en) * 2001-12-12 2010-10-21 Do-Coop Technologies Ltd. Solid-fluid composition and uses thereof
US20060177852A1 (en) * 2001-12-12 2006-08-10 Do-Coop Technologies Ltd. Solid-fluid composition
US20030236205A1 (en) * 2002-06-21 2003-12-25 Zhang David Y. Hybridization signal amplification method (HSAM) nanostructures for diagnostic and therapeutic uses
WO2004000278A1 (en) * 2002-06-21 2003-12-31 Mount Sinai School Of Medicine Of New York University Hybridization signal amplification method (hsam) nanostructures for diagnostic and therapeutic uses
WO2004009664A2 (en) 2002-07-19 2004-01-29 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
EP1531757A2 (en) * 2002-07-19 2005-05-25 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7297348B2 (en) 2002-07-19 2007-11-20 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
EP1531757A4 (en) * 2002-07-19 2011-05-04 Omeros Corp Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
JP2010180248A (en) * 2002-07-19 2010-08-19 Omeros Corp Biodegradable triblock copolymer, synthesis method therefore, and hydrogel and biomaterial made therefrom
US11008404B2 (en) 2003-05-12 2021-05-18 Helion Biotech Aps Antibodies to MASP-2
US9096676B2 (en) 2003-05-12 2015-08-04 Helion Biotech Aps Antibodies to MASP-2
US11225526B2 (en) 2003-05-12 2022-01-18 Helion Biotech Aps Antibodies to MASP-2
US10189909B2 (en) 2003-05-12 2019-01-29 Helion Biotech Aps Antibodies to MASP-2
US11008405B2 (en) 2003-05-12 2021-05-18 Helion Biotech Aps Antibodies to MASP-2
US20070009528A1 (en) * 2003-05-12 2007-01-11 Natlmmune A/S Antibodies to masp-2
US20060211599A1 (en) * 2003-10-31 2006-09-21 Wakamoto Pharmaceutical Co., Ltd. Reversibly heat-gelable aqueous composition
US20050106230A1 (en) * 2003-11-17 2005-05-19 Young Janel E. Drug-enhanced adhesion prevention
US20060282158A1 (en) * 2003-11-17 2006-12-14 Taheri Syde A Temporary absorbable venous occlusive stent and superficial vein treatment method
US20060282159A1 (en) * 2003-11-17 2006-12-14 Taheri Syde A Temporary absorbable venous occlusive stent and superficial vein treatment method
EP2460537A1 (en) 2004-06-10 2012-06-06 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2446901A1 (en) 2004-06-10 2012-05-02 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2386317A1 (en) 2004-06-10 2011-11-16 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP3530288A2 (en) 2004-06-10 2019-08-28 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP3047858A1 (en) 2004-06-10 2016-07-27 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
EP2386315A1 (en) 2004-06-10 2011-11-16 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2386316A1 (en) 2004-06-10 2011-11-16 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US11884742B2 (en) 2004-06-10 2024-01-30 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20100074899A1 (en) * 2004-06-10 2010-03-25 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
EP2465534A1 (en) 2004-06-10 2012-06-20 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
EP2465535A1 (en) 2004-06-10 2012-06-20 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2382991A1 (en) 2004-06-10 2011-11-02 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060002937A1 (en) * 2004-06-10 2006-01-05 University Of Leicester Methods for treating conditions associated with MASP-2 dependent complement activation
EP2392350A1 (en) 2004-06-10 2011-12-07 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2457585A1 (en) 2004-06-10 2012-05-30 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2446900A1 (en) 2004-06-10 2012-05-02 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2446902A1 (en) 2004-06-10 2012-05-02 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20100324667A1 (en) * 2004-06-22 2010-12-23 Boston Scientific Scimed, Inc. Implantable medical devices with anti-microbial and biodegradable matrices
US8192481B2 (en) 2004-06-22 2012-06-05 Boston Scientific Scimed, Inc. Implantable medical devices with anti-microbial and biodegradable matrices
US20050283224A1 (en) * 2004-06-22 2005-12-22 Scimed Life Systems, Inc. Implantable medical devices with antimicrobial and biodegradable matrices
US7356368B2 (en) 2004-07-21 2008-04-08 Boston Scientific Scimed, Inc. Light-activated anti-infective coatings and devices made thereof
US7402320B2 (en) 2004-08-31 2008-07-22 Vnus Medical Technologies, Inc. Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure
US20060052823A1 (en) * 2004-08-31 2006-03-09 Mirizzi Michael S Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure
US20060052822A1 (en) * 2004-08-31 2006-03-09 Mirizzi Michael S Apparatus and material composition for permanent occlusion of a hollow anatomical structure
US8333786B2 (en) 2005-01-25 2012-12-18 Covidien Lp Method and apparatus for implanting an occlusive structure
US20090159088A1 (en) * 2005-01-25 2009-06-25 Karabey Halil I Method for permanent occlusion of fallopian tube
US20060212055A1 (en) * 2005-01-25 2006-09-21 Karabey Halil I Expandable occlusive structure
US20110172695A1 (en) * 2005-01-25 2011-07-14 Tyco Healthcare Group, L.P. Method and apparatus for implanting an occlusive structure
US7972354B2 (en) 2005-01-25 2011-07-05 Tyco Healthcare Group Lp Method and apparatus for impeding migration of an implanted occlusive structure
US8333201B2 (en) 2005-01-25 2012-12-18 Covidien Lp Method for permanent occlusion of fallopian tube
US9017350B2 (en) 2005-01-25 2015-04-28 Covidien Lp Expandable occlusive structure
US20060212127A1 (en) * 2005-01-25 2006-09-21 Karabey Halil I Structures for permanent occlusion of a hollow anatomical structure
US8262695B2 (en) 2005-01-25 2012-09-11 Tyco Healthcare Group Lp Structures for permanent occlusion of a hollow anatomical structure
US8968353B2 (en) 2005-01-25 2015-03-03 Covidien Lp Method and apparatus for impeding migration of an implanted occlusive structure
US8011370B2 (en) 2005-01-25 2011-09-06 Tyco Healthcare Group Lp Method for permanent occlusion of fallopian tube
US20060211643A1 (en) * 2005-02-03 2006-09-21 Agency For Science, Technology And Research Polycations capable of forming complexes with nucleic acids
US7883688B2 (en) 2005-02-03 2011-02-08 Agency For Science, Technology And Research Polycationic polyrotaxanes capable of forming complexes with nucleic acids
WO2007077561A2 (en) * 2006-01-04 2007-07-12 Do-Coop Technologies Ltd. Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
WO2007077561A3 (en) * 2006-01-04 2008-12-31 Do Coop Technologies Ltd Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
US20090004296A1 (en) * 2006-01-04 2009-01-01 Do-Coop Technologies Ltd. Antiseptic Compositions and Methods of Using Same
US20090029340A1 (en) * 2006-01-04 2009-01-29 Do-Coop Technologies Ltd. Cryoprotective Compositions and Methods of Using Same
US20090253613A1 (en) * 2006-01-04 2009-10-08 Do-Coop Technologies Ltd. Solid-Fluid Composition
CN100371020C (en) * 2006-01-27 2008-02-27 中山大学 In situ quick preparation method of injectable supermolecular structure water gel and its uses
EP3067067A1 (en) 2006-04-03 2016-09-14 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
US20070248640A1 (en) * 2006-04-20 2007-10-25 Karabey Halil I Occlusive implant and methods for hollow anatomical structure
US9017361B2 (en) 2006-04-20 2015-04-28 Covidien Lp Occlusive implant and methods for hollow anatomical structure
US20100041103A1 (en) * 2007-01-04 2010-02-18 Do-Coop Technologies Ltd. Composition and method for enhancing cell growth and cell fusion
US20100086929A1 (en) * 2007-01-04 2010-04-08 Do-Coop Technologies Ltd. Detection of analytes
US20110274725A1 (en) * 2008-09-16 2011-11-10 Louis Breton Decomposable biocompatible hydrogels and system and method for using same
WO2010104584A2 (en) 2009-03-13 2010-09-16 Gore Enterprise Holdings, Inc. Articles and methods of treating vascular conditions
US20100233266A1 (en) * 2009-03-13 2010-09-16 Cleek Robert L Articles and methods of treating vascular conditions
JP2012520297A (en) * 2009-03-13 2012-09-06 ゴア エンタープライズ ホールディングス，インコーポレイティド Products and methods for the treatment of vascular diseases
AU2010223044B2 (en) * 2009-03-13 2013-07-18 W. L. Gore & Associates, Inc. Articles and methods of treating vascular conditions
EP3560483A1 (en) 2009-03-13 2019-10-30 W.L. Gore & Associates, Inc. Articles and methods of treating vascular conditions
CN102348473A (en) * 2009-03-13 2012-02-08 戈尔企业控股股份有限公司 Articles and methods of treating vascular conditions
AU2013245532B2 (en) * 2009-03-13 2014-09-25 W. L. Gore & Associates, Inc. Articles and methods of treating vascular conditions
US20190247306A1 (en) * 2009-03-13 2019-08-15 W. L. Gore & Associates, Inc. Articles and methods of treating vascular conditions
US10314783B2 (en) 2009-03-13 2019-06-11 W. L. Gore & Associates, Inc. Articles and methods of treating vascular conditions
WO2010104584A3 (en) * 2009-03-13 2011-01-20 Gore Enterprise Holdings, Inc. Articles and methods of treating vascular conditions
WO2010120541A2 (en) 2009-03-31 2010-10-21 University Of Washington Compositions and methods for modulating the activity of complement regulatory proteins on target cells
WO2010122246A3 (en) * 2009-04-23 2011-04-07 Centre National De La Recherche Scientifique -Cnrs - Method for forming cyclodextrin polymer and lipophilic compound emulsions, resulting emulsions, and compositions including said emulsions
FR2944700A1 (en) * 2009-04-23 2010-10-29 Centre Nat Rech Scient METHOD OF FORMING EMULSIONS BASED ON CYCLODEXTRIN POLYMERS AND LIPOPHILIC COMPOUNDS, EMULSIONS THUS OBTAINED, AND COMPOSITIONS COMPRISING SAID EMULSIONS
US8741347B2 (en) 2009-04-23 2014-06-03 Centre National de la Recherche Scientifique—CNRS Method for forming cyclodextrin polymer and lipophilic compound emulsions, resulting emulsions, and compositions including said emulsions
WO2011047346A1 (en) 2009-10-16 2011-04-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
EP3150635A2 (en) 2009-10-16 2017-04-05 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US20110091450A1 (en) * 2009-10-16 2011-04-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US8652477B2 (en) 2009-10-16 2014-02-18 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
WO2011156761A1 (en) 2010-06-10 2011-12-15 University Of Washington Through Its Center For Commercialization Methods and systems for adenovirus interaction with desmoglein 2 (dsg2)
US10202465B2 (en) 2011-04-08 2019-02-12 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2012139081A2 (en) 2011-04-08 2012-10-11 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
US10059776B2 (en) 2011-04-08 2018-08-28 Omerus Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP3287142A1 (en) 2011-04-08 2018-02-28 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
EP3964233A1 (en) 2011-04-08 2022-03-09 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
US8951522B2 (en) 2011-04-08 2015-02-10 University Of Leicester Methods for treating conditions associated with MASP-2 dependent complement activation
US10683367B2 (en) 2011-05-04 2020-06-16 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
US9475885B2 (en) 2011-05-04 2016-10-25 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
US9011860B2 (en) 2011-05-04 2015-04-21 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
EP3725811A2 (en) 2011-05-04 2020-10-21 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
US11613589B2 (en) 2011-05-04 2023-03-28 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
US10047165B2 (en) 2011-05-04 2018-08-14 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
EP3366307A1 (en) 2012-04-06 2018-08-29 Omeros Corporation Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
WO2013180834A2 (en) 2012-04-06 2013-12-05 Omeros Corporation Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
EP4119577A2 (en) 2012-06-18 2023-01-18 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
EP3878865A2 (en) 2012-06-18 2021-09-15 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
EP3058951A1 (en) 2012-06-18 2016-08-24 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
WO2013192240A2 (en) 2012-06-18 2013-12-27 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
WO2014052322A1 (en) 2012-09-25 2014-04-03 University Of Washington Through Its Center For Commercialization Desmoglein 2 (dsg2) binding proteins and uses therefor
US9765122B2 (en) 2013-01-18 2017-09-19 University Of Washington Through Its Center For Commercialization Theragnostic particles
WO2014113759A1 (en) 2013-01-18 2014-07-24 University Of Washington Through Its Center For Commercialization Theragnostic particles
US20150306231A1 (en) * 2013-01-28 2015-10-29 Terumo Kabushiki Kaisha Stabilized protein gel preparation
EP2949336B1 (en) * 2013-01-28 2018-09-05 National University Corporation Kumamoto University Stabilized protein gel preparation
JPWO2014115882A1 (en) * 2013-01-28 2017-01-26 国立大学法人 熊本大学 Gel formulation with stabilized protein
WO2014144542A2 (en) 2013-03-15 2014-09-18 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US11045544B2 (en) 2013-03-15 2021-06-29 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
WO2015023961A1 (en) 2013-08-15 2015-02-19 International Flavors & Fragrances Inc. Polyurea or polyurethane capsules
US11525011B2 (en) 2013-10-17 2022-12-13 Omeros Corporation Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndrome
EP3750919A1 (en) 2013-10-17 2020-12-16 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
WO2015058143A1 (en) 2013-10-17 2015-04-23 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
WO2016172699A1 (en) 2015-04-24 2016-10-27 International Flavors & Fragrances Inc. Delivery systems and methods of preparing the same
EP3101171A1 (en) 2015-06-05 2016-12-07 International Flavors & Fragrances Inc. Malodor counteracting compositions
CN105534878A (en) * 2015-12-07 2016-05-04 四川大学 Preparation of dual-responsive injectable supramolecular intelligent hydrogel
US10736960B2 (en) 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
WO2017143174A1 (en) 2016-02-18 2017-08-24 International Flavors & Fragrances Inc. Polyurea capsule compositions
WO2017161364A1 (en) 2016-03-18 2017-09-21 International Flavors & Fragrances Inc. Silica microcapsules and methods of preparing same
US10870708B2 (en) 2016-03-31 2020-12-22 University Of Leicester Methods for inhibiting angiogenesis in a subject in need thereof
US11027015B2 (en) 2016-08-01 2021-06-08 Omeros Corporation Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
US10639369B2 (en) 2016-08-01 2020-05-05 Omeros Corporation Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
US11883493B2 (en) 2016-08-01 2024-01-30 Omeros Corporation Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
EP4209264A1 (en) 2016-09-16 2023-07-12 International Flavors & Fragrances Inc. Microcapsule compositions stabilized with viscosity control agents
EP3300794A2 (en) 2016-09-28 2018-04-04 International Flavors & Fragrances Inc. Microcapsule compositions containing amino silicone
EP3425036A1 (en) 2017-05-30 2019-01-09 International Flavors & Fragrances Inc. Branched polyethyleneimine microcapsules
US11013772B2 (en) 2017-08-15 2021-05-25 Omeros Corporation Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
WO2019036460A1 (en) 2017-08-15 2019-02-21 Omeros Corporation Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
US11896621B2 (en) 2017-08-15 2024-02-13 Omeros Corporation Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
WO2020131956A1 (en) 2018-12-18 2020-06-25 International Flavors & Fragrances Inc. Hydroxyethyl cellulose microcapsules
US11807641B2 (en) 2019-12-04 2023-11-07 Omeros Corporation MASP-2 inhibitors and methods of use
WO2023009514A1 (en) 2021-07-27 2023-02-02 International Flavors & Fragrances Inc. Biodegradable microcapsules
EP4124383A1 (en) 2021-07-27 2023-02-01 International Flavors & Fragrances Inc. Biodegradable microcapsules
WO2023049260A1 (en) 2021-09-23 2023-03-30 International Flavors & Fragrances Inc. Biodegradable microcapsules
EP4154974A1 (en) 2021-09-23 2023-03-29 International Flavors & Fragrances Inc. Biodegradable microcapsules
WO2023133191A1 (en) 2022-01-07 2023-07-13 International Flavors & Fragrances Inc. Biodegradable chitosan microcapsules
EP4209265A1 (en) 2022-01-07 2023-07-12 International Flavors & Fragrances Inc. Biodegradable chitosan microcapsules
EP4212239A1 (en) 2022-01-14 2023-07-19 International Flavors & Fragrances Inc. Biodegradable prepolymer microcapsules
WO2023137121A1 (en) 2022-01-14 2023-07-20 International Flavors & Fragrances Inc. Biodegradable prepolymer microcapsules
WO2023194821A1 (en) 2022-04-03 2023-10-12 Qrons Inc. Therapeutic polypseudorotaxane hydrogels
CN115350100A (en) * 2022-07-08 2022-11-18 横琴孔雀大讲堂教育科技有限公司 Hydrogel microcapsule wrapping bioactive components, preparation method thereof and application thereof in cosmetics

Also Published As

Publication number Publication date
US8003125B2 (en) 2011-08-23
SG98393A1 (en) 2003-09-19

Similar Documents

Publication Publication Date Title
US8003125B2 (en) Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
EP0863745B1 (en) Thermosensitive biodegradable polymers based on poly(ether-ester) block copolymers
Fang et al. Cyclodextrin-based host–guest supramolecular hydrogels for local drug delivery
CA2672551C (en) Biodegradable block copolymeric compositions for drug delivery
Tamada et al. The development of polyanhydrides for drug delivery applications
AU2003249317B2 (en) Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
EP0863933B1 (en) Novel hydrogels containing triblock copolymers, and preparation and use thereof
CN101415442B (en) Controlled release gels
JP2015034172A (en) Taxane-containing amphiphilic block copolymer micelle composition and manufacturing method of the same
US20060233857A1 (en) Degradable elastomeric network
KR20010022708A (en) Injectable biodegradable block copolymer gels for use in drug delivery
JPH11510837A (en) Multi-block biodegradable hydrogels for use as controlled release and tissue treatment agents for drug delivery
US7744919B2 (en) Block copolymer micelle composition having an enhanced drug-loading capacity and sustained release
JP2001526246A (en) Methods and compositions for drug delivery and / or adhesion prevention
CN101186706B (en) Preparation method for PEG series gel nano particles
Loh et al. Biodegradable thermogelling polymers
KR100418916B1 (en) Process for Preparing Sustained Release Form of Micelle Employing Conjugate of Anticancer Drug and Biodegradable Polymer
Kumbhar et al. In situ gel forming injectable drug delivery system
Ghosh Recent research and development in synthetic polymer-based drug delivery systems
CN105708789A (en) Drug-loaded nanofiber microsphere/hydrogel compound and preparation method and application thereof
WO2002094324A1 (en) Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
CN114369259B (en) PH dissociable temperature-sensitive hydrogel, preparation method and application thereof
Luo et al. Preparation, thermal response mechanisms and biomedical applications of thermosensitive hydrogels for drug delivery
CN111423568B (en) Polyethylene glycol and amino modified polycaprolactone triblock copolymer, nanoparticles thereof, temperature-sensitive gel and application
JP4303196B2 (en) Gelatin derivatives and polymeric micelles comprising the derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSTITUTE OF MATERIALS RESEARCH & ENGINEERING, SIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, JUN;YU, HANRY;LEONG, KAM;REEL/FRAME:012215/0434;SIGNING DATES FROM 20010511 TO 20010514

Owner name: INSTITUTE OF MATERIALS RESEARCH & ENGINEERING, SIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, JUN;YU, HANRY;LEONG, KAM;SIGNING DATES FROM 20010511 TO 20010514;REEL/FRAME:012215/0434

AS Assignment

Owner name: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, SINGA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF MATERIALS RESEARCH AND ENGINEERING;REEL/FRAME:023532/0056

Effective date: 20030205

ZAAA Notice of allowance and fees due

Free format text: ORIGINAL CODE: NOA

ZAAB Notice of allowance mailed

Free format text: ORIGINAL CODE: MN/=.

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT, TEXAS

Free format text: SECURITY INTEREST;ASSIGNOR:OMEROS CORPORATION;REEL/FRAME:040575/0110

Effective date: 20161103

AS Assignment

Owner name: OMEROS CORPORATION, WASHINGTON

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CRG SERVICING LLC;REEL/FRAME:047573/0577

Effective date: 20181115

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20230823